Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr Olawaiye on the Potential Role of Afuresertib Plus Paclitaxel in pAKT-Expressing Platinum-Resistant Ovarian Cancer

March 31st 2025

Alexander B. Olawaiye, MD, discusses future research that could inform the use of afuresertib plus paclitaxel in platinum-resistant ovarian cancer.

Dr Hardesty on Updated Data With Frontline Niraparib Plus Bevacizumab Maintenance in Advanced Ovarian Cancer

March 31st 2025

Melissa M. Hardesty, MD, discusses OS and subgroup data from the OVARIO study of niraparib and bevacizumab maintenance in newly diagnosed ovarian cancer.

Current Treatment Approaches and Challenges in Platinum-Resistant Ovarian Cancer

March 31st 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss current treatment approached in platinum-resistant ovarian cancer.

Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer

March 31st 2025

Relacorilant plus nab-paclitaxel demonstrated improved PFS and OS in platinum-resistant ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 3/23

March 30th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

Dr Myers on HRQOL Outcomes With Mirvetuximab Soravtansine in Ovarian Cancer

March 28th 2025

Tashanna K. Myers, MD, discusses HRQOL findings in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine in MIRASOL.

Oncolytic Adenovirus TILT-123 Plus Pembrolizumab Is Tolerable in Platinum-Resistant/Refractory Ovarian Cancer

March 26th 2025

TILT-123 plus pembrolizumab was active in platinum-resistant/refractory ovarian cancer in the phase 1a PROTA trial and the phase 1b portion is ongoing.

TTFields/Paclitaxel Fails to Boost OS in Platinum-Resistant Ovarian Cancer But Shows Potential in Key Subgroup

March 26th 2025

The addition of tumor treating fields to paclitaxel did not lead to a statistically significant overall survival improvement in platinum-resistant ovarian cancer.

Mirvetuximab Soravtansine Stakes Claim as SOC in FRα+ Platinum-Resistant Ovarian Cancer

March 26th 2025

Toon Van Gorp, MD, PhD, discusses the final analysis of the phase 3 MIRASOL trial of mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer.

Nemvaleukin Fails to Show OS Benefit Over Chemotherapy in Platinum-Resistant Ovarian Cancer

March 25th 2025

The development of nemvaleukin in platinum-resistant ovarian cancer will be discontinued based on interim OS data from the phase 3 ARTISTRY-7 trial.

The OncFive: Top Oncology Articles for the Week of 3/16

March 22nd 2025

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

Dr Cho on Niraparib Rechallenge Plus Bevacizumab in Platinum-Sensitive, Recurrent Ovarian Cancer

March 21st 2025

Hyun-Woong Cho, MD, PhD, discusses the efficacy of maintenance therapy with niraparib plus bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer

March 18th 2025

Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.

Abemaciclib/Hormonal Therapy Combo Yields Clinical Activity in LGSOC/EEC

March 18th 2025

Treatment with abemaciclib plus hormonal therapy showed promise in LGSOC/EEC but not in HGSOC, and larger studies are needed to validate these findings.

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer

March 17th 2025

The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer

March 17th 2025

Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.

Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer

March 17th 2025

The combination of avutometinib and defactinib produced durable responses in recurrent low-grade serous ovarian cancer.

Pembrolizumab Plus Lenvatinib Elicits Clinically Meaningful Responses in Platinum-Resistant HGSOC

March 17th 2025

The combination of pembrolizumab and lenvatinib showed promising activity including durable responses in patients with platinum-resistant HGSOC.

Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer

March 16th 2025

Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer With Low/Medium FRα Expression

March 16th 2025

Luveltamab tazevibulin was active and safe in patients with platinum-resistant ovarian cancer and a FRα expression of at least 25%.